Showing results (51-60 of 74) with videos related to
Sort By:
Pageof 8
Hepatology (Baltimore, Md.)|July 9, 2017
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failureDavid Wyles, Heiner Wedemeyer, Ziv Ben-Ari, et al.The New England Journal of Medicine|February 4, 2011
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in malesAnna R Giuliano, Joel M Palefsky, Stephen Goldstone, et al.Lancet (London, England)|December 4, 2014
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialEric Lawitz, Edward Gane, Brian Pearlman, et al.The Lancet. HIV|October 2, 2015
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trialJürgen K Rockstroh, Mark Nelson, Christine Katlama, et al.The New England Journal of Medicine|May 15, 2007
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseasesSuzanne M Garland, Mauricio Hernandez-Avila, Cosette M Wheeler, et al.Lancet (London, England)|December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialMark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.Hepatology Communications|May 16, 2018
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infectionJacob George, Eduard Burnevich, I-Shyan Sheen, et al.Journal of Hepatology|August 21, 2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trialJan Sperl, Gabor Horvath, Waldemar Halota, et al.Hepatology (Baltimore, Md.)|February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trialGraham R Foster, Kosh Agarwal, Matthew E Cramp, et al.Annals of Internal Medicine|August 8, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort StudyJason Grebely, Gregory J Dore, Frederick L Altice, et al.Pageof 8